National Cancer Institute-ko ikertzaileekin lankidetzan egindako argitalpenak (52)

2023

  1. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

    Annals of Epidemiology, Vol. 77, pp. 1-12

  2. Evaluation of trefoil factor 3 as a non-invasive biomarker of gastric intestinal metaplasia and gastric cancer in a high-risk population

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 6, pp. 411-418

2022

  1. Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR-Driven Lung Cancer

    Advanced Science, Vol. 9, Núm. 26

2021

  1. Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy

    Cancer Letters, Vol. 499, pp. 279-289

2010

  1. Molecular characterization of the Gγ-globin-tagtransgenic mouse model of hormone refractory prostate cancer: comparison to human prostate cancer

    Prostate, Vol. 70, Núm. 6, pp. 630-645

  2. VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop

    Experimental Cell Research, Vol. 316, Núm. 4, pp. 554-567

2008

  1. Human adrenomedullin up-regulates interleukin-13 receptor α2 chain in prostate cancer in vitro and in vivo: A novel approach to sensitize prostate cancer to anticancer therapy

    Cancer Research, Vol. 68, Núm. 22, pp. 9311-9317

  2. Identification of VEGF-regulated genes associated with increased lung metastatic potential: Functional involvement of tenascin-C in tumor growth and lung metastasis

    Oncogene, Vol. 27, Núm. 40, pp. 5373-5384

2007

  1. 2-Methoxyestradiol induces mammary gland differentiation through amphiregulin-epithelial growth factor receptor-mediated signaling: Molecular distinctions from the mammary gland of pregnant mice

    Endocrinology, Vol. 148, Núm. 3, pp. 1266-1277

  2. Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis

    International Journal of Cancer, Vol. 120, Núm. 10, pp. 2096-2109

2006

  1. Adrenomedullin: An Esoteric Juggernaut of Human Cancers

    Handbook of Biologically Active Peptides (Elsevier Inc.), pp. 453-458

  2. Distinct tumor stage-specific inhibitory effects of 2-methoxyestradiol in a breast cancer mouse model associated with Id-1 expression

    Cancer Research, Vol. 66, Núm. 7, pp. 3495-3503

2005

  1. Gene expression profiling identifies IL-13 receptor α2 chain as a therapeutic target in prostate tumor cells overexpressing adrenomedullin

    International Journal of Cancer, Vol. 114, Núm. 6, pp. 870-878

  2. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms

    Oncogene, Vol. 24, Núm. 5, pp. 790-800

  3. Prostate cancer and the genomic revolution: Advances using microarray analyses

    Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, Vol. 576, Núm. 1-2, pp. 66-79

2004

  1. Altered expression of adhesion molecules and epithelial-mesenchymal transition in silica-induced rat lung carcinogenesis

    Laboratory Investigation, Vol. 84, Núm. 8, pp. 999-1012

  2. Application of Gene Expression Profiling for Validating Models of Human Breast Cancer

    Toxicologic Pathology, Vol. 32, Núm. SUPPL. 1, pp. 84-89

  3. Depressed adrenomedullin in the embryonic transforming growth factor-β1 null mouse becomes elevated postnatally

    International Journal of Developmental Biology, Vol. 48, Núm. 1, pp. 67-70

  4. Expression of complement factor H by lung cancer cells: Effects on the activation of the alternative pathway of complement

    Cancer Research, Vol. 64, Núm. 17, pp. 6310-6318

  5. Genomic Approaches to Understanding Mammary Tumor Progression in Transgenic Mice and Responses to Therapy

    Clinical Cancer Research